Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Catheter Precision, Inc. (VTAK)
USD0.64
+0.08 (+13.89%)
US AMEX Healthcare Medical - Devices
Address
1670 Highway 160 West 29708
Fort Mill, SC, US
Fort Mill, SC, US
CEO
David A. Jenkins
Website
catheterprecision.com
IPO
2018-09-27
CIK 1716621 ISIN US74933X7084
Description
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in August 2023.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.64
+0.08 (+13.89%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.30
Float Shares
1.06M
Free Float %
98.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.07% | -6.62% | -5.69% | -51.18% | -53.11% | -54.64% | -84.66% | -99.62% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.64
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-02 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-14.61
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%+95.0% ★ Q1'26: +28.7% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-138.0% Q1'26: -286.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-1,704.6% Q1'26: -1,522.8% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-2,347.3% Q1'26: -1,371.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-184.7% Q1'26: -48.7% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+33,011.3% Q1'26: +19,324.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.22× Q1'26: -1.19× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
6.26M
est: 6.95M (-10.0%)
|
7.20M
est: 7.86M (-8.4%)
|
259.0K
est: 4.75M (-94.5%)
|
22.0K
est: 2.45M (-99.1%)
|
442.0K
est: 1.90M (-76.7%)
|
420.0K
est: 600.0K (-30.0%)
|
819.0K
est: 3.80M (-78.4%)
|
10.20M
10.20M – 10.20M
+168.4% YoY
|
| EBITDA |
-30.18M
est: -6.95M (-334.3%)
|
-54.94M
est: -7.86M (-599.3%)
|
-33.04M
est: -4.75M (-595.6%)
|
-25.85M
est: -2.45M (-955.0%)
|
-15.11M
est: -1.90M (-695.3%)
|
-11.30M
est: -600.0K (-1,783.7%)
|
-17.11M
est: -3.80M (-350.2%)
|
-10.20M
-10.20M – -10.20M
-168.4% YoY
|
| EBIT |
-30.81M
est: -6.95M (-343.2%)
|
-56.69M
est: -7.86M (-621.6%)
|
-35.40M
est: -4.75M (-645.4%)
|
-27.25M
est: -2.45M (-1,012.1%)
|
-17.19M
est: -1.90M (-804.5%)
|
-13.41M
est: -600.0K (-2,135.2%)
|
-19.22M
est: -3.80M (-405.9%)
|
-10.20M
-10.20M – -10.20M
-168.4% YoY
|
| Net Income |
-30.83M
est: -1.75T (+100.0%)
|
-56.96M
est: -3.16T (+100.0%)
|
-36.05M
est: -945.62B (+100.0%)
|
-25.07M
est: -118.28B (+100.0%)
|
-70.57M
est: -7.45B (+99.1%)
|
-16.64M
est: -182.73B (+100.0%)
|
-17.18M
est: -129.35B (+100.0%)
|
-65.70B
-65.70B – -65.70B
+49.2% YoY
|
| SGA |
30.44M
est: 2.81B (-98.9%)
|
51.55M
est: 3.18B (-98.4%)
|
24.53M
est: 1.92B (-98.7%)
|
15.48M
est: 992.06M (-98.4%)
|
17.12M
est: 769.35M (-97.8%)
|
11.35M
est: 233.36M (-95.1%)
|
12.08M
est: 1.48B (-99.2%)
|
3.97B
3.97B – 3.97B
+168.4% YoY
|
| EPS |
-4,175.51
est: -535,597.25 (+99.2%)
|
-5,416.22
est: -969,000.00 (+99.4%)
|
-1,060.77
est: -289,750.00 (+99.6%)
|
-248.22
est: -36,242.50 (+99.3%)
|
-12.99
est: -2,281.90 (+99.4%)
|
-6.68
est: -169.10 (+96.0%)
|
-15.90
est: -119.70 (+86.7%)
|
-60.80
-60.80 – -60.80
+49.2% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-7.60M
OE per share TTM
-0.50
Owner's Yield
-0.42%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
198.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
3
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Daniel B. Asher | 162.0K | 9.50% | — | 162.0K | — | 149.5K | HC, IN | United States of America | 2024-09-12 | ↗ |
| 2 | Intracoastal Capital LLC | 162.0K | 9.50% | — | 162.0K | — | 149.5K | OO | United States of America | 2024-09-12 | ↗ |
| 3 | Mitchell P. Kopin | 162.0K | 9.50% | — | 162.0K | — | 149.5K | HC, IN | United States of America | 2024-09-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GEODE CAPITAL MANAGEMENT, LLC | 47.7K +47.7K (+100.0%) | 48.1K +48.1K (+100.0%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD1.01 +0.0% | 1 qtrs NEW |
| 2 | MILLENNIUM MANAGEMENT LLC | 13.1K -21.6K (-62.2%) | 13.3K -50.3K (-79.1%) | 0.00% -0.003 pp | 0.00% +0.000 pp | USD1.83 -44.8% | 2 qtrs — |
| 3 | UBS GROUP AG | 759.00 -779.0 (-50.7%) | 767.00 -2.0K (-72.8%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD1.83 -44.8% | 2 qtrs — |
| 4 | — | 13.00 +— (+0.0%) | 13.00 -10.0 (-43.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.77 -42.9% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
650.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+650,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-26 | JENKINS DAVID A | Director / Officer | A-Award | A | Options (Right to Buy) | 40,000 | 1.15 | 46.0K | 40,000 | D | ↗ |
| 2026-03-26 | Caruso James Joseph | Director | A-Award | A | Options (Right to Buy) | 40,000 | 1.15 | 46.0K | 40,000 | D | ↗ |
| 2026-03-26 | COLOMBATTO MARTIN J | Director | A-Award | A | Options (Right to Buy) | 40,000 | 1.15 | 46.0K | 40,000 | D | ↗ |
| 2026-03-26 | Arno Andrew | Director | A-Award | A | Options (Right to Buy) | 40,000 | 1.15 | 46.0K | 40,000 | D | ↗ |
| 2026-03-26 | ANDERSON PHILIP J | Officer | A-Award | A | Options (Right to Buy) | 40,000 | 1.15 | 46.0K | 40,000 | D | ↗ |
| 2026-02-12 | JENKINS DAVID A | Director / Officer | J-Other | A | Series J Preferred Stock | 2,491 | 1.56 | 3.9K | 2,491 | D | ↗ |
| 2025-12-31 | JENKINS DAVID A | Officer | J-Other | A | Series M Common Stock Purchase Warrant | 170,000 | 1.56 | 265.2K | 170,000 | I | ↗ |
| 2025-12-05 | JENKINS DAVID A | Officer | C-Conversion | A | Common Stock | 30,844 | 0.00 | — | 34,579 | I | ↗ |
| 2025-12-05 | Caruso James Joseph | Director | C-Conversion | A | Common Stock | 41 | 0.00 | — | 50 | D | ↗ |
| 2025-08-12 | JENKINS DAVID A | Director / Officer | A-Award | A | Options (Right to Buy) | 500,000 | 0.18 | 90.0K | 500,000 | D | ↗ |
| 2025-08-12 | Caruso James Joseph | Director | A-Award | A | Options (Right to Buy) | 50,000 | 0.18 | 9.0K | 50,000 | D | ↗ |
| 2025-08-12 | COLOMBATTO MARTIN J | Director | A-Award | A | Options (Right to Buy) | 50,000 | 0.18 | 9.0K | 50,000 | D | ↗ |
| 2025-08-12 | Arno Andrew | Director | A-Award | A | Options (Right to Buy) | 50,000 | 0.18 | 9.0K | 50,000 | D | ↗ |
| 2025-01-29 | Jacques Marie-Claude | Officer | A-Award | A | Stock Option | 125,000 | 0.42 | 52.5K | 125,000 | D | ↗ |
| 2025-01-29 | JENKINS DAVID A | Officer | A-Award | A | Stock Option | 450,000 | 0.42 | 189.0K | 450,000 | D | ↗ |
| 2025-01-29 | Caruso James Joseph | Director | A-Award | A | Stock Option | 100,000 | 0.42 | 42.0K | 100,000 | D | ↗ |
| 2025-01-29 | COLOMBATTO MARTIN J | Director | A-Award | A | Stock Option | 100,000 | 0.42 | 42.0K | 100,000 | D | ↗ |
| 2025-01-29 | Arno Andrew | Director | A-Award | A | Stock Option | 100,000 | 0.42 | 42.0K | 100,000 | D | ↗ |
| 2025-01-06 | ANDERSON PHILIP J | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-08-30 | Jenkins Family Charitable Institute | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 265,226 | — | ↗ |
| 2024-07-03 | Arno Andrew | Director | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2024-05-01 | Jacques Marie-Claude | Officer | — | D | Common Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-01-23 | JENKINS DAVID A | Director / Officer | P-Purchase | A | Common Stock | 9,528 | 0.60 | 5.7K | 329,856 | — | ↗ |
| 2024-01-22 | JENKINS DAVID A | Director / Officer | P-Purchase | A | Common Stock | 9,528 | 0.43 | 4.1K | 320,328 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-8.7K
Shares Outstanding
1.08M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-03-23 | DEFA14A | ↗ |
| 2026-03-23 | DEF 14A | ↗ |
| 2026-03-13 | PRE 14A | ↗ |
| 2025-09-15 | DEF 14A | ↗ |
| 2025-09-04 | PRE 14A | ↗ |
| 2025-09-04 | DEFA14A | ↗ |
| 2025-06-09 | DEFA14A | ↗ |
| 2025-06-09 | DEFA14A | ↗ |
| 2025-06-09 | DEFA14A | ↗ |
| 2025-06-09 | DEF 14A | ↗ |
| 2025-05-30 | PRE 14A | ↗ |
| 2025-01-07 | DEFA14A | ↗ |
| 2024-11-25 | DEFA14A | ↗ |
| 2024-11-25 | DEF 14A | ↗ |
| 2024-11-15 | PRE 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David A. Jenkins | Chief Executive Officer, Chief Commercial Officer & Executive Chairman | 300.0K | male |
| Margrit Thomassen | Controller | 197.8K | female |
| Philip Anderson | Chief Financial Officer | — | male |
ESG Rating
ESG Score History MEDICAL - DEVICES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VTAK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
